# Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients

> **NCT04566432** · — · RECRUITING · sponsor: **Geneplus-Beijing Co. Ltd.** · enrollment: 250 (estimated)

## Conditions studied

- Lung Neoplasms
- Lung Cancer, Nonsmall Cell
- Adenocarcinoma of Lung
- Squamous Cell Lung Cancer

## Interventions

- **OTHER:** Observation

## Key facts

- **NCT ID:** NCT04566432
- **Lead sponsor:** Geneplus-Beijing Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-06-30
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2024-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04566432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04566432, "Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04566432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*